Aaron R. Weiss

Aaron R. Weiss

Auto-generated profile, based on publicly available information

Aaron R. Weiss

Department of Pediatrics, MaineHealth Maine Medical Center, Portland, ME, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AWAaron R. Weiss
Aaron R. Weiss
ELElizabeth R. Lyden
Elizabeth R. Lyden
JAJames R. Anderson
James R. Anderson
DHDouglas S. Hawkins
Douglas S. Hawkins
SSSheri L. Spunt
Sheri L. Spunt
RWRichard B. Womer
Richard B. Womer
Purpose: To simplify the recommended staging evaluation by correlating tumor and clinical features with patterns of distant metastasis in newly diagnosed patients with embryonal rhabdomyosarcoma (ERMS) or alveolar rhabdomyosarcoma (ARMS). Patients and Methods: Patient data from the Intergroup Rhabdomyosarcoma Study Group and the Children's Oncology Group over two periods were analyzed: 1991 to 1997 and 1999 to 2004. We used recursive partitioning analyses to identify factors (including histology, age, regional nodal and distant metastatic status, tumor size, local invasiveness, and primary site) that divided patients into subsets with the most different rates of metastatic disease. Results: Of the 1,687 patients analyzed, 5.7% had lung metastases, 4.8% had bone involvement, and 6% had bone marrow (BM) involvement. Rhabdomyosarcoma (RMS) without local invasion (T1) had a low rate of metastasis for all distant sites, especially ERMS (0% bone, 0% BM). ARMS with local invasion (T2) had a higher rate of metastasis for all distant sites (13% lung, 18% bone, 23% BM). ERMS, T2 also had a higher rate of metastatic lung involvement (9%). The likelihood of bone or BM involvement increased in the presence of lung metastases (41% with, 6% without). Regional nodal metastases (N1) predicted a high rate of metastasis in all distant sites (14% lung, 14% bone, 18% BM). A staging algorithm was developed. Conclusion: Staging studies in childhood RMS can be tailored to patients' presenting characteristics. Bone marrow aspirate and biopsy and bone scan are unnecessary in at least one third of patients with RMS.

20 July 2020 in The Lancet Oncology
Verified
Journal Article
Closed access
AWAaron R Weiss
Aaron R Weiss
YCYen-Lin Chen
Yen-Lin Chen
TSThomas J Scharschmidt
Thomas J Scharschmidt
YCYueh-Yun Chi
Yueh-Yun Chi
JTJing Tian
Jing Tian
DWDian Wang
Dian Wang

20 February 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AWAaron R. Weiss
Aaron R. Weiss
DHDouglas J. Harrison
Douglas J. Harrison
Soft tissue sarcomas (STS) represent a heterogeneous group of extraskeletal mesenchymal tumors that affect individuals throughout the entire age continuum. Despite this pervasive influence, key differences exist in the presentation of these sarcomas across varying age groups that have prevented a more uniform approach to management. Notably, rhabdomyosarcoma (RMS) is more common in children, while most nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) subtypes are more prevalent in adults. Older patients with NRSTS appear to have more molecularly complex biology and often present with more advanced disease compared with children. Poorer outcome disparities are observed in older patients with RMS despite receiving similar treatment as younger patients. In this review, we highlight differences in epidemiology, biology, and management paradigms for pediatric and adult patients with STS and explore opportunities for a unified approach to enhance the care and outcomes within the AYA population.

20 October 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TCThomas Cash
Thomas Cash
MKMark D. Krailo
Mark D. Krailo
ABAllen B. Buxton
Allen B. Buxton
BPBruce R. Pawel
Bruce R. Pawel
JHJohn Healey
John Healey
RWRichard B. Womer
Richard B. Womer
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Long-term outcomes from Children's Oncology Group study AEWS0031 were assessed to determine whether the survival advantage of interval-compressed chemotherapy (ICC) was maintained over 10 years in patients with localized Ewing sarcoma (ES). AEWS0031 enrolled 568 eligible patients. Patients were randomly assigned to receive vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide alternating once every 3 weeks (standard timing chemotherapy [STC]) versus once every 2 weeks (ICC). For this updated report, one patient was excluded because of uncertainty of original diagnosis. The 10-year event-free survival (EFS) was 70% with ICC compared with 61% with STC ( P = .03), and 10-year overall survival (OS) was 76% with ICC compared with 69% with STC ( P = .04). There was no difference in the 10-year cumulative incidence of second malignant neoplasms (SMNs; PC [see Data Supplement, online only] = .5). A test for interaction demonstrated that ICC provided greater risk reduction for patients with tumor volume ≥200 mL than for patients with tumors <200 mL, but no evidence for a significant interaction in other subgroups defined by age, primary site, and histologic response. With longer-term follow-up, ICC for localized ES is associated with superior EFS and OS without an increased risk for SMN compared with STC. ICC is associated with improved outcomes even in adverse-risk patient groups.

28 April 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
AFAndrea Ferrari
Andrea Ferrari
DODaniel Orbach
Daniel Orbach
MSMonika Sparber-Sauer
Monika Sparber-Sauer
DWDavid O. Walterhouse
David O. Walterhouse
KPKristian W. Pajtler
Kristian W. Pajtler
AWAaron R. Weiss
Aaron R. Weiss

1 November 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AWAaron R. Weiss
Aaron R. Weiss
YCYen-Lin Chen
Yen-Lin Chen
TSThomas J. Scharschmidt
Thomas J. Scharschmidt
WXWei Xue
Wei Xue
ZGZhengya Gao
Zhengya Gao
SSSheri L. Spunt
Sheri L. Spunt
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. ARST1321 was a phase II study designed to compare the near complete pathologic response rate after preoperative chemoradiation with/without pazopanib in children and adults with intermediate-/high-risk chemotherapy-sensitive body wall/extremity non-Rhabdomyosarcoma Soft Tissue Sarcoma (ClinicalTrials.gov identifier: NCT02180867 ). Enrollment was stopped early following a predetermined interim analysis that found the rate of near complete pathologic response to be significantly greater with the addition of pazopanib. As a planned secondary aim of the study, the outcome data for this cohort were analyzed. Eight-five eligible patients were randomly assigned to receive (regimen A) or not receive (regimen B) pazopanib in combination with ifosfamide and doxorubicin + preoperative radiotherapy followed by primary resection at week 13 and then further chemotherapy at week 25. As of December 31, 2021, at a median survivor follow-up of 3.3 years (range, 0.1-5.8 years), the 3-year event-free survival for all patients in the intent-to-treat analysis was 52.5% (95% CI, 34.8 to 70.2) for regimen A and 50.6% (95% CI, 32 to 69.2) for regimen B ( P = .8677, log-rank test); the 3-year overall survival was 75.7% (95% CI, 59.7 to 91.7) for regimen A and 65.4% (95% CI, 48.1 to 82.7) for regimen B ( P = .1919, log-rank test). Although the rate of near complete pathologic response was significantly greater with the addition of pazopanib, outcomes were not statistically significantly different between the two regimens.